Charles River Laboratories International, Inc. CRL
334.32 USD +1.22 (+0.37%)
As ofNov 19, 2026, 9:59 AM EST
331.17 Day range 343.57
149.93 52-week range 376.10
- YTD
- +67.60%
- 1 year
- +106.83%
News
zacks.com Should You Continue to Hold Charles River Stock in Your Portfolio? CRL's improving DSA demand, rising bookings and stronger solvency support its outlook, but competition and currency fluctuations pose risks.
defenseworld.net Fifth Third Bancorp Purchases 4,299 Shares of Charles River Laboratories International, Inc. $CRL Fifth Third Bancorp raised its holdings in Charles River Laboratories International, Inc. (NYSE: CRL) by 24.1% in the third quarter, according to the company in its most recent Form 13F filing with…
seekingalpha.com Ariel Small Cap Value Concentrated Q3 2026 Portfolio Activity The Ariel Small Cap Value Concentrated Composite posted a -5.99% gross return (-6.13% net of fees) for the quarter. Zebra Technologies was the top contributor during the quarter following a strong…
businesswire.com Charles River Laboratories to Present at Jefferies Global Healthcare Conference WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Jefferies Global Healthcare Conference.
defenseworld.net Alpha Teknova (NASDAQ:TKNO) versus Charles River Laboratories International (NYSE:CRL) Critical Analysis Alpha Teknova (NASDAQ: TKNO - Get Free Report) and Charles River Laboratories International (NYSE: CRL - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
defenseworld.net Commonwealth Equity Services LLC Buys 31,177 Shares of Charles River Laboratories International, Inc. $CRL Commonwealth Equity Services LLC grew its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 733.4% in the undefined quarter, according to the company in its most recent filing…
seekingalpha.com Ariel Small Cap Value Q3 2026 Portfolio Activity Bar-code manufacturer Zebra Technologies was the top contributor during the quarter following a strong earnings report and raise to full-year guidance. Norwegian Cruise Line Holdings declined during…
zacks.com GMRS vs. CRL: Which Stock Should Value Investors Buy Now? Investors interested in Medical Services stocks are likely familiar with GMR Solutions Inc. (GMRS) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better…
businesswire.com Charles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River has announced a series of strategic investments and operational enhancements across its global Microbial Solutions network.
benzinga.com Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says Charles River Laboratories will buy Frontage's bioanalysis unit for $470 million in cash to expand its clinical drug testing scale.benzinga.com Charles River Laboratories To Acquire Frontage Holdings Corporation’s Bioanalysis And DMPK Operations In Pennsylvania For ~$470M In Cash Plus Additional Payments Of Up To $75M The transaction is expected to close during the first half of 2027, subject to required shareholder and regulatory approvals, and other customary closing conditions. Frontage’s laboratory testing…
benzinga.com UBS Maintains Buy on Charles River, Raises Price Target to $387 UBS analyst Kevin Caliendo maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $357 to $387.
benzinga.com RBC Capital Maintains Outperform on Charles River, Raises Price Target to $352 RBC Capital analyst Ryan Halsted maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $322 to $352.
benzinga.com Barclays Maintains Overweight on Charles River, Raises Price Target to $375 Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Overweight and raises the price target from $330 to $375.
benzinga.com Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $400 Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $330 to $400.
benzinga.com Charles River Q3 2026 Earnings Call Transcript Charles River (NYSE:CRL) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…benzinga.com Charles River Widens FY2026 Adj EPS Guidance from $11.45 to $11.35-$11.55 vs $11.38 Est; Raises FY2026 Sales Guidance from $3.915B to $3.940B-$3.960B vs $3.916B Est Charles River (NYSE:CRL) widens FY2026 Adj EPS guidance from $11.45 to $11.35-$11.55 vs $11.38 analyst estimate. Raises FY2026 sales outlook from $3.915 billion to $3.940 billion-$3.960 billion vs…
benzinga.com Charles River Laboratories' Virtual Control Group Database And Methodology To Be Used In An Upcoming Good Laboratory Practice-Compliant Study For Ipsen This collaboration highlights Charles River’s and Ipsen’s dedication and commitment to championing the 3Rs (Replacement, Reduction, and Refinement of animal use in research) while upholding the…
benzinga.com Charles River Laboratories Announces Research Collaboration Agreement With FDA And Labcorp For Developing Sensitive Screening Tools To Quantify And Rank Abuse Potential Of New Drugs Joint research effort seeks to improve abuse potential assessment tools to support drug development and public health decision-makingCharles River Laboratories International, Inc. (NYSE:CRL) today…
benzinga.com $1000 Invested In Charles River 15 Years Ago Would Be Worth This Much Today Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 4.33% on an annualized basis producing an average annual return of 17.1%. Currently, Charles River has a market…
benzinga.com SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.finance.sina.com.cn 康方生物依沃西闯关FDA受阻:创新药出海折戟破局策 11月14日下午,第十九届“谈家桢生命科学奖”在复旦大学揭晓。康方生物(09926)创始人、董事长、总裁兼首席执行官夏瑜获得谈家桢生命科学产业化奖,是14位获奖者之一。康方生物最有价值的资产,是其全球首个获批上市的PD-1/VEGF双特异性抗体依沃西单抗。 就在转天,太平洋彼岸传来一则依沃西的坏消息。11月15日,康方生物的海外合作伙伴Summit…
finance.sina.com.cn 查尔斯河实验室收涨0.33%,成交额1.72亿美元 11月19日,查尔斯河实验室(CRL)收涨0.33%,报333.25美元,成交额1.72亿美元,市值159.68亿美元。 公司最新财报显示,季度营收9.83亿美元,同比下降2.2%;净利润3.33亿美元,同比增长512.01%。
seekingalpha.com Ariel Small/Mid Cap Value Q3 2026 Commentary Ariel Small/Mid Cap Value Composite returned -4.07% gross of fees (-4.18% net of fees), outperforming both the Russell 2500 Value Index & the Russell 2500 Index.
finance.yahoo.com NRx (NRXP) Q3 2026 Earnings Call Transcript Operator: Good day, ladies and gentlemen, and welcome to the NRx Pharmaceuticals Third Quarter 2026 Results Conference Call. ...
finance.yahoo.com Invesco S&P 500 Equal Weight (RSP) Buys $0.6 Million More AppLovin on Nov. 17 The fund added $212.6 million across all 503 holdings, with AppLovin, Viatris and Fiserv each drawing about $0.6 million.
marketscreener.com Potter & Moore PLC Announces Board Changes Potter & Moore PLC appointed Nick Mustoe as Non-Executive Chairman, effective November 18, 2026. Nick is a highly experienced ...
seekingalpha.com Tracking John Rogers' Ariel Investments Portfolio - Q3 2026 Update Ariel Investments’ 13F portfolio fell to $9.61 billion in Q3 2026; Generac rose 40%, and Madison Square Garden Entertainment ...
finance.yahoo.com Should You Continue to Hold Charles River Stock in Your Portfolio? CRL's improving DSA demand, rising bookings and stronger solvency support its outlook, but competition and currency ...
finance.yahoo.com Global Preclinical CRO Services Market Opportunities and Strategies to 2035 | Capitalize on AI, Oncology and Biomarkers with Charles River, WuXi AppTec, Eurofins and Pharmaron Boost ROI via AI-enabled models, biomarker and PK assays, oncology services, screening partnerships, emerging-market expansion and value-based pricing.Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- ...
finance.yahoo.com Charles River Laboratories International (CRL) Recovers Following Cyclical Contraction Cooke & Bieler, an investment management firm, released its third-quarter investor letter for “All Cap Value Equity Strategy.
markets.businessinsider.com Commentary on the Tender Closing of the Town Hall Link White Site A consortium of CapitaLand Development, Far East Organization and Sing Holdings submitted the top bid of $1.82 billion for ...
marketscreener.com Potter & Moore Plc Reports Earnings Results for the Half Year Ended September 30, 2026 Potter & Moore Plc reported earnings results for the half year ended September 30, 2026. For the half year, the company ...
baynews9.com Discover Crystal River releases 2025 Visitor Impact report showing tourist impact on the area CRYSTAL RIVER, Fla. — Citrus County’s yearly visitor economic impact report for 2025 is in and it’s showing some pretty big numbers. According to Discover Crystal River's report, more than $428 ...
theglobeandmail.com Should You Continue to Hold Charles River Stock in Your Portfolio? Charles River Laboratories International, Inc.’s CRL Discovery and Safety Assessment (“DSA”) segment is showing improving ...
tw.stock.yahoo.com 新北市再生醫療公會跨區串聯,打造國際細胞製造供應鏈 【財訊快報/記者何美如報導】《再生醫療雙法》上路將滿一周年,新北市再生醫療商業同業公會積極整合產業資源,理事長暨樂迦再生(6891)董事長邱俊榮18日表示,公會已串聯台北市、新竹縣同業,建構「台灣再生醫療黃金三角」,並於10月率領會員前往日本橫濱參加 ...
